Clinical Trials | April 22, 2026
Ultomiris shows strong interim results in Phase III IgA nephropathy trial
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
